Supplementary Table 1 from Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)